DK0674524T3 - Stabile, lyofiliserede, farmaceutiske sammensætninger af G-CSF - Google Patents

Stabile, lyofiliserede, farmaceutiske sammensætninger af G-CSF

Info

Publication number
DK0674524T3
DK0674524T3 DK94902772T DK94902772T DK0674524T3 DK 0674524 T3 DK0674524 T3 DK 0674524T3 DK 94902772 T DK94902772 T DK 94902772T DK 94902772 T DK94902772 T DK 94902772T DK 0674524 T3 DK0674524 T3 DK 0674524T3
Authority
DK
Denmark
Prior art keywords
csf
pct
lyophilized
stable
pharmaceutical compositions
Prior art date
Application number
DK94902772T
Other languages
Danish (da)
English (en)
Inventor
Uwe Michaelis
Rainer Rudolph
Gerhard Winter
Heinrich Woog
Original Assignee
Roche Diagnostics Gmbh
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, Boehringer Mannheim Gmbh filed Critical Roche Diagnostics Gmbh
Application granted granted Critical
Publication of DK0674524T3 publication Critical patent/DK0674524T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94902772T 1992-12-18 1993-12-15 Stabile, lyofiliserede, farmaceutiske sammensætninger af G-CSF DK0674524T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4242863A DE4242863A1 (de) 1992-12-18 1992-12-18 Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
PCT/EP1993/003543 WO1994014465A1 (de) 1992-12-18 1993-12-15 Stabile lyophilisierte pharmazeutische zubereitungen von g-csf

Publications (1)

Publication Number Publication Date
DK0674524T3 true DK0674524T3 (da) 1999-02-01

Family

ID=6475691

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94902772T DK0674524T3 (da) 1992-12-18 1993-12-15 Stabile, lyofiliserede, farmaceutiske sammensætninger af G-CSF

Country Status (14)

Country Link
US (1) US5919443A (ko)
EP (1) EP0674524B1 (ko)
JP (1) JPH08504784A (ko)
KR (1) KR100266145B1 (ko)
AT (1) ATE165007T1 (ko)
AU (1) AU676573B2 (ko)
CA (1) CA2151732C (ko)
DE (2) DE4242863A1 (ko)
DK (1) DK0674524T3 (ko)
ES (1) ES2117781T3 (ko)
HU (1) HU220256B (ko)
NZ (1) NZ258912A (ko)
SG (1) SG66740A1 (ko)
WO (1) WO1994014465A1 (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2180206A1 (en) * 1995-06-30 1996-12-31 Motoya Ohshika Freeze-dried preparation for pharmaceutical use
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6776983B1 (en) * 1998-03-06 2004-08-17 Chugai Seiyaku Kabushiki Kaisha Protein free formulations
DE69940051D1 (de) * 1998-06-26 2009-01-22 Otsuka Pharma Co Ltd Wasserlösliche trockene zusammensetzungen
DE60035260T2 (de) * 1999-02-22 2007-10-18 The University Of Connecticut, Farmington Neue albuminfreie faktor viii formulierungen
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
WO2001048117A1 (fr) * 1999-12-24 2001-07-05 Otsuka Pharmaceutical Co., Ltd. Compositions seches contenant un acide amine hydrophobe
DE60103940T2 (de) 2000-02-29 2005-07-28 Pfizer Products Inc., Groton Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
MXPA02009485A (es) * 2000-03-31 2003-03-10 Kirin Brewery Preparacion en polvo para administracion a traves de la mucosa, que comprende un farmaco de alto peso molecular y que muestra una estabilidad mejorada en almacenamiento.
EP1329224A4 (en) * 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd PREPARATIONS OF STABILIZED SOLUTIONS OVER A LONG PERIOD OF TIME
US20030129162A1 (en) * 2000-09-12 2003-07-10 Lau Allan S. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
CA2422060A1 (en) * 2000-09-12 2002-03-21 Genetrol Biotherapeutics, Inc. Compositions comprising mixtures of human cytokines and methods of producing the same
US20020141970A1 (en) * 2001-03-05 2002-10-03 Pettit Dean K. Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
DE10163459A1 (de) * 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
DE10204792A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Immuncytokine
AU2003268664A1 (en) * 2002-09-26 2004-04-19 Shionogi And Co., Ltd. Stabilized protein compositions
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
DE10348550A1 (de) * 2003-10-20 2005-06-16 Hexal Biotech Forschungsgmbh Stabile wässrige G-CSF-haltige Zusammensetzungen
CA2536041A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
SI21639A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtski pripravek, ki vsebuje nemicelarne sulfobetaine
DE102004022928A1 (de) * 2004-05-10 2005-12-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend neuartige Oligosacharidgemische und Verfahren zu deren Herstellung
PL1658848T3 (pl) 2004-10-29 2007-12-31 Pharma Mar Sa Preparaty zawierające ekteinascydynę i disacharyd
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
CN104288756A (zh) * 2006-04-14 2015-01-21 曼金德公司 高血糖素样肽1(glp-1)药物制剂
WO2008107908A1 (en) * 2007-03-05 2008-09-12 Cadila Healthcare Limited Compositions comprising peg- interferon alpha conjugates and raffinose as cryoprotectant
WO2008122118A1 (en) * 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
AU2008235044B2 (en) * 2007-04-05 2011-08-25 Sandoz Ag Stable aqueous G-CSF formulations
EP2471510A1 (de) 2007-08-27 2012-07-04 BioGeneriX AG Flüssigformulierung von G-CSF
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
CN102378635A (zh) 2009-01-16 2012-03-14 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
CN102869679B (zh) * 2010-04-27 2015-11-25 Scil技术股份有限公司 稳定的水性mia/cd-rap制剂
TWI480288B (zh) * 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
DK3744319T3 (da) 2019-05-28 2023-01-16 Ilkogen Ilac Sanayi Ve Ticaret A S Stabil lyofiliseret formulering til hybrid fc-fusioneret g-csf
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
US5104651A (en) * 1988-12-16 1992-04-14 Amgen Inc. Stabilized hydrophobic protein formulations of g-csf
JP3249147B2 (ja) * 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
US5416071A (en) * 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE69306755T2 (de) * 1992-01-21 1997-04-10 Stanford Res Inst Int Verbessertes verfahren zur herstellung von mikronisierter polypeptidarzneimitteln
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
AU3599995A (en) * 1994-10-04 1996-04-26 Csl Limited Controlled-release pharmaceutical preparations

Also Published As

Publication number Publication date
AU676573B2 (en) 1997-03-13
ATE165007T1 (de) 1998-05-15
WO1994014465A1 (de) 1994-07-07
EP0674524B1 (de) 1998-04-15
JPH08504784A (ja) 1996-05-21
HU220256B (hu) 2001-11-28
HU9501764D0 (en) 1995-08-28
KR950703987A (ko) 1995-11-17
ES2117781T3 (es) 1998-08-16
HUT74269A (en) 1996-11-28
US5919443A (en) 1999-07-06
NZ258912A (en) 1997-06-24
AU6808694A (en) 1994-07-19
SG66740A1 (en) 1999-09-21
KR100266145B1 (ko) 2000-09-15
EP0674524A1 (de) 1995-10-04
DE4242863A1 (de) 1994-06-23
CA2151732A1 (en) 1994-07-07
CA2151732C (en) 2008-02-12
DE59308415D1 (de) 1998-05-20

Similar Documents

Publication Publication Date Title
DK0674524T3 (da) Stabile, lyofiliserede, farmaceutiske sammensætninger af G-CSF
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
DE69326250D1 (de) Neuropeptide y antagoniste
ES2113652T3 (es) Pamoato de risperidona.
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
NO963133D0 (no) 12,13-isotaksolanaloger, antineoplastisk anvendelse og farmasöytiske preparater inneholdende disse
DK0579681T3 (da) Krystallinsk tiagabin-hydrochlorid-monohydrat, dets fremstilling og dets anvendelse
MY102929A (en) Aqueous pharmaceutical formulations of piroxicam monohydrate
DE69420872T2 (de) Hgh enthaltende pharmazeutische zubereitungen
ATE104551T1 (de) S-adenosylmethionin zur behandlung von pankreatitis und der immunabstossung des pankreastransplantates.
AU8332791A (en) Oral pharmaceutical compositions containing melatonin
ITRM920349A1 (it) Composizioni farmaceutiche contenenti il-6
DK0656780T3 (da) Lægemidler, der indeholder diphosphonsyrer og salte deraf.
IL99471A0 (en) Pharmaceutical compositions containing pyridylmethylsulphinyl-1h-benzimidazole derivatives as active ingredient therein
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
IL106272A0 (en) Pharmaceutical compositions comprising il-6
DE59303446D1 (de) Neue bis-phenyl-hexene
DK630088D0 (da) Azelastinembonat, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater med indhold af denne forbindelse som aktivt middel
FI970318A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiitoreina käyttökelpoisia yhdisteitä
DK0412941T3 (da) Phospholipider til behandling af dissemineret sklerose